Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Change in Receivables (2016 - 2025)

Guided Therapeutics' Change in Receivables history spans 15 years, with the latest figure at $8000.0 for Q2 2025.

  • For Q2 2025, Change in Receivables rose 366.67% year-over-year to $8000.0; the TTM value through Sep 2025 reached $5000.0, up 225.0%, while the annual FY2024 figure was -$6000.0, 300.0% down from the prior year.
  • Change in Receivables for Q2 2025 was $8000.0 at Guided Therapeutics, up from -$1000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $22000.0 in Q4 2021 and bottomed at -$32000.0 in Q3 2022.
  • The 5-year median for Change in Receivables is -$1000.0 (2023), against an average of $769.23.
  • The largest YoY upside for Change in Receivables was 600.0% in 2022 against a maximum downside of 1700.0% in 2022.
  • A 5-year view of Change in Receivables shows it stood at $22000.0 in 2021, then crashed by 245.45% to -$32000.0 in 2022, then surged by 112.5% to $4000.0 in 2023, then plummeted by 150.0% to -$2000.0 in 2024, then surged by 500.0% to $8000.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Change in Receivables are $8000.0 (Q2 2025), -$1000.0 (Q1 2025), and -$2000.0 (Q4 2024).